

AMENDMENTS TO THE CLAIMS:

1. (Previously presented) A purified polypeptide comprising an antibody, or a functional fragment thereof, that induces apoptosis of a neoplastic cell to which it binds, but does not induce apoptosis of a non-neoplastic cell, wherein said antibody specifically binds to at least one of HT-29 (ATCC Accession No. HTB-38; DSMZ Accession No. ACC 299), CACO-2 (ATCC Accession No. HBT-37; DSMZ Accession No. ACC 169), COLO-320 (DSMZ Accession No. ACC 144), COLO-206F (DSMZ Accession No. ACC 21), or COLO-678 (DSMZ Accession No. 194) cells and not to non-neoplastic cells.

2. (Previously presented) The purified polypeptide of claim 1, wherein said neoplastic cell is a colorectal adenocarcinoma, ovarian cancer, squamous cell lung carcinoma, or lobular mammary carcinoma cell.

3. Cancelled.

4. (Currently amended) A The purified polypeptide of claim 1, wherein said polypeptide comprising an antibody, or a functional fragment thereof, that inhibits cell proliferation when bound to a neoplastic cell, but does not inhibit cell proliferation of a non-neoplastic cell, ~~wherein said antibody specifically binds to at least one of HT 29 (ATCC Accession No. HTB 38; DSMZ Accession No. ACC 299), CACO 2 (ATCC~~

~~Accession No. HBT 37; DSMZ Accession No. ACC 169), COLO 320 (DSMZ Accession No. ACC 144), COLO 206F (DSMZ Accession No. ACC 21), or COLO 678 (DSMZ Accession No. 194) cells and not to non-neoplastic cells.~~

5. (Cancelled).

6. (Cancelled).

7. (Currently amended) The purified polypeptide of claim 1, ~~3, 4, or 6~~, wherein said polypeptide comprises a sequence that is substantially identical to the amino acid sequence of SEQ ID NO:1.

8. (Currently amended) The purified polypeptide of claim 1, ~~3, 4, or 6~~, wherein said polypeptide comprises a sequence that is substantially identical to the amino acid sequence of SEQ ID NO:3.

9. (Previously presented) A purified polypeptide comprising an antibody, or functional fragment thereof, wherein said polypeptide comprises the amino acid sequence of SEQ ID NO:1.

10. (Previously presented) A purified polypeptide comprising an antibody, or functional fragment thereof, wherein said polypeptide comprises the amino acid sequence of SEQ ID NO:3.

11. (Previously presented) A purified polypeptide comprising an antibody, or functional fragment thereof, wherein said polypeptide comprises the amino acid sequence of SEQ ID NOS:1 and 3.

12. (Currently amended) The purified polypeptide of claim 1,~~3,4,6,9,10, or 11~~, wherein said antibody is a human antibody.

13. (Currently amended) The purified polypeptide of claim 1,~~3,4,6,9,10, or 11~~, wherein said antibody is a monoclonal antibody.

14. (Currently amended) The purified polypeptide of claim 1,~~3,4,6,9,10, or 11~~, wherein said polypeptide is a functional fragment selected from the group consisting of V_L, V_H, F_V, F_C, Fab, Fab', and F(ab')₂.

15. (Currently amended) The purified polypeptide of claim 1,~~3,4,6,9,10, or 11~~, wherein said polypeptide is a functional fragment comprising a fragment that is substantially identical to the sequence of SEQ ID NO:1 or SEQ ID NO:3.

16. (Currently amended) The purified polypeptide of claim 1, ~~3, 4, 6, 9, 10, or 11~~, wherein said polypeptide is a functional fragment comprising a fragment of the sequence of SEQ ID NO:1 or SEQ ID NO:3.

17. – 53. (Cancelled).